Brokerages Set Anixa Biosciences Inc (NASDAQ:ANIX) Price Target at $9.00

Anixa Biosciences Inc (NASDAQ:ANIX) has been assigned a consensus recommendation of “Hold” from the five brokerages that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $9.00.

ANIX has been the topic of a number of recent research reports. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research note on Wednesday, February 4th. Wall Street Zen cut Anixa Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Zacks Research downgraded Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Anixa Biosciences in a research report on Monday, December 29th.

Insider Activity

In other news, Director Arnold M. Baskies purchased 10,000 shares of the firm’s stock in a transaction on Wednesday, January 28th. The shares were bought at an average cost of $3.04 per share, with a total value of $30,400.00. Following the purchase, the director directly owned 135,000 shares of the company’s stock, valued at approximately $410,400. This trade represents a 8.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 26.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Anixa Biosciences

Institutional investors and hedge funds have recently modified their holdings of the company. NewEdge Advisors LLC purchased a new stake in Anixa Biosciences in the 2nd quarter worth approximately $33,000. Cetera Investment Advisers purchased a new position in shares of Anixa Biosciences during the 4th quarter worth $35,000. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Anixa Biosciences by 2,000.0% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after purchasing an additional 10,000 shares during the last quarter. Benjamin Edwards Inc. purchased a new stake in shares of Anixa Biosciences in the second quarter valued at $37,000. Finally, Millennium Management LLC purchased a new stake in shares of Anixa Biosciences in the fourth quarter valued at $38,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Trading Up 0.7%

NASDAQ:ANIX opened at $3.04 on Tuesday. The company has a market capitalization of $101.48 million, a P/E ratio of -8.69 and a beta of 0.53. The firm has a 50-day moving average price of $3.10 and a two-hundred day moving average price of $3.55. Anixa Biosciences has a twelve month low of $2.33 and a twelve month high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings results on Monday, January 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). On average, equities research analysts predict that Anixa Biosciences will post -0.41 earnings per share for the current year.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.